Redox mechanisms in hepatic chronic wound healing and fibrogenesis

Fibrogenesis and Tissue Repair

Volumn 1, Issue 1, 2008, Pages

  Novo, Erica ^a   Parola, Maurizio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69949160564     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-1-5     Document Type: Review

References (358)

1. Commoner B, Townsend J, Pake GE. Free radicals in biological materials. Nature 1954, 174:689-691. 10.1038/174689a0, 13213980.
2. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol 1956, 11:298-300.
3. Slater TF. Necrogenic action of carbon tetrachloride in the rat: a speculative mechanism based on activation. Nature 1966, 209:36-40. 10.1038/209036a0, 5925327.
4. McCord JM, Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969, 244:6049-6055.
5. Slater TF. Free Radical Mechanisms in Tissue Injury 1972, London, UK: Pion Ltd.
6. Harman D. The aging process. Proc Natl Acad Sci USA 1981, 78:7124-7128. 10.1073/pnas.78.11.7124, 6947277.
7. Cadenas E. Biochemistry of oxygen toxicity. Ann Rev Biochem 1989, 58:79-110. 10.1146/annurev.bi.58.070189.000455, 2673022.
8. Cadenas E, Davies KJ. Mitochondrial free radical generation, oxidative stress and aging. Free Radic Biol Med 2000, 29:222-230. 10.1016/S0891-5849(00)00317-8, 11035250.
9. West JD, Marnett LJ. Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol 2006, 19:173-194. 10.1021/tx050321u, 16485894.
10. White AA, Crawford KM, Patt CS, Lad PJ. Activation of soluble guanylate cyclase from rat lung by incubation or by hydrogen peroxide. J Biol Chem 1976, 251:7304-7312.
11. Mittal CK, Murad F. Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine 3',5'-monophosphate formation. Proc Natl Acad Sci USA 1977, 74:4360-4364. 10.1073/pnas.74.10.4360, 22077.
12. Ignarro LJ, Kadowitz PJ. The pharmacological and physiological role of cGMP in vascular smooth muscle relaxation. Ann Pharmacol Toxicol 1985, 25:171-191.
13. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987, 92:639-646.
14. Thannickal VJ, Farnburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 2000, 279:L1005-L1028.
15. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
16. Soberman RJ. The expanding network of redox signaling: new observations, complexities, and perspectives. J Clin Invest 2003, 111:571-574.
17. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci 2003, 28:509-514. 10.1016/S0968-0004(03)00174-9, 13678963.
18. D'Autrèaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007, 8:813-824. 10.1038/nrm2256, 17848967.
19. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991, 11:81-128. 10.1016/0891-5849(91)90192-6, 1937131.
20. Dianzani MU. 4-Hydroxynonenal and cell signaling. Free Rad Res 1998, 28:553-560.
21. Parola M, Bellomo G, Robino G, Barrera G, Dianzani MU. 4-Hydroxynonenal as a biological signal: molecular bases and pathophysiological implication. Antioxid Redox Signal 1999, 1:255-284. 10.1089/ars.1999.1.3-255, 11229439.
22. Poli G, Schaur RJ. 4-Hydroxynonenal in the phatomechanisms of oxidative stress. IUBMB Life 2000, 50:315-321. 10.1080/15216540051081092, 11327326.
23. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 2003, 42:318-343. 10.1016/S0163-7827(03)00014-6, 12689622.
24. Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc Med 2001, 11:93-102. 10.1016/S1050-1738(01)00111-6, 11686009.
25. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2003, 23:599-622.
26. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003, 91:7A-11A. 10.1016/S0002-9149(02)03144-2, 12645638.
27. Pennathur S, Heinecke JW. Oxidative stress and endothelial dysfunction in vascular disease. Curr Diab Rep 2007, 7:257-264. 10.1007/s11892-007-0041-3, 17686400.
28. Kaneto H, Katakami N, Kawamori D, Miyatsuka T, Sakamoto K, Matsuoka TA, Matsuhisa M, Yamasaki Y. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid Redox Signal 2007, 9:355-366. 10.1089/ars.2006.1465, 17184181.
29. Papaharalambus CA, Griendling KK. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc Med 2007, 17:48-54. 10.1016/j.tcm.2006.11.005, 17292046.
30. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 2003, 111:583-593.
31. Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev 2006, 25:695-705. 10.1007/s10555-006-9037-8, 17160708.
32. Klein JA, Ackerman SL. Oxidative stress, cell cycle and neurodegeneration. J Clin Invest 2003, 111:785-793.
33. Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal 2006, 8:1997-2006. 10.1089/ars.2006.8.1997, 17034345.
34. Zhu X, Su B, Wang X, Smith MA, Perry G. Causes of oxidative stress in Alzheimer diseases. Cell Mol Life Sci 2007, 64:2202-2210. 10.1007/s00018-007-7218-4, 17605000.
35. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001, 35:297-306. 10.1016/S0168-8278(01)00142-8, 11580156.
36. Zamara E, Novo E, Parola M. Oxidative stress and liver fibrosis: from liver injury to the modulation of cell signaling and response. Liver Diseases: Biochemical Mechanisms and New Therapeutic Insights 2004, 1:93-114. Enfield, NH: Science Publishers USA;, Ali S, Mann DA, Friedman SL.
37. Farrell GC, Larter CZ. Nonalcoholic fatty liver diseases: from steatosis to cirrhosis. Hepatology 2006, (Suppl 1):S99-S112.
38. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc 2006, 65:278-280. 10.1079/PNS2006496, 16923312.
39. Rahman I, Biswas SK, Kode A. Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222-239. 10.1016/j.ejphar.2005.12.087, 16500642.
40. Rahman I, Yang SR, Biswas SK. Current concepts of redox signaling in the lungs. Antioxid Redox Signal 2006, 8:681-689. 10.1089/ars.2006.8.681, 16677111.
41. Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006, 8:76-87. 10.1089/ars.2006.8.76, 16487040.
42. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine 1999, Oxford, UK: Oxford University Press.
43. Babior BM. NADPH oxidase: an update. Blood 1999, 93:1464-1476.
44. Vignais PV. The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell Mol Life Sci 2002, 59:1428-1459. 10.1007/s00018-002-8520-9, 12440767.
45. Genestra M. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cell Signal 2007, 19:1807-1819. 10.1016/j.cellsig.2007.04.009, 17570640.
46. Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 2007, 43:332-347. 10.1016/j.freeradbiomed.2007.03.027, 17602948.
47. De Minicis S, Bataller R, Brenner DA. NADPH oxidase in the liver: defensive, offensive, or fibrogenic?. Gastroenterology 2006, 131:272-275. 10.1053/j.gastro.2006.05.048, 16831609.
48. De Minicis S, Brenner DA. NOX in liver fibrosis. Arch Biochem Biophys 2007, 462:266-272. 10.1016/j.abb.2007.04.016, 17531188.
49. Chiarugi P, Fiaschi T. Redox signalling in anchorage-dependent cell growth. Cell Signal 2007, 19:672-682. 10.1016/j.cellsig.2006.11.009, 17204396.
50. Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 2000, 129:195-208. 10.1016/S0009-2797(00)00203-9, 11154741.
51. Vazquez-Vivar J, Kalyanaramam B. Generation of superoxide from nitric oxide synthase. FEBS 2000, 481:304-307.
52. Rojkind M, Domininguez-Rosales JA, Nieto N, Greenwel P. Role of hydrogen peroxide and oxidative stress in healing responses. Cell Mol Life Sci 2002, 59:1872-1891. 10.1007/PL00012511, 12530519.
53. Morrow JD, Awad JA, Kato T, Takahashi K, Badr KF, Roberts LJ, Burk RF. Formation of novel non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in carbon tetrachloride hepatotoxicity. J Clin Invest 1992, 92:2502-2507.
54. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?. Br J Pharmacol 2004, 142:231-255. 10.1038/sj.bjp.0705776, 15155533.
55. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C. Isoprostanes and hepatic fibrosis. Mol Aspects Med 2008, 29:43-49. 10.1016/j.mam.2007.09.011, 18061254.
56. Comporti M, Signorini C, Arezzini B, Vecchio D, Monaco B, Gardi C. F2-isoprostanes are not just markers of oxidative stress. Free Radic Biol Med 2008, 44:247-256. 10.1016/j.freeradbiomed.2007.10.004, 17997380.
57. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med 1997, 22:287-305. 10.1016/S0891-5849(96)00327-9, 8958154.
58. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424. 10.1152/physrev.00029.2006, 17237348.
59. Sase K, Michel T. Expression and regulation of endothelial nitric oxide synthase. Trends Cardiovasc Med 1997, 7:28-37.
60. Archer SL, Huang JMC, Hampl V, Nelson DP, Shultz PJ, Weir EK. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin sensitive K-channel by a cGMP-dependent protein kinase. Proc Natl Acad Sci USA 1994, 91:7583-7587. 10.1073/pnas.91.16.7583, 7519783.
61. Beckman JS. Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 1996, 9:836-844. 10.1021/tx9501445, 8828918.
62. Beckman JS. The physiological and pathological chemistry of nitric oxide. Nitric Oxide: Principles and Actions 1996, 1-82. San Diego, CA: Academic Press, Lancaster JR, Orlando FL.
63. Butler AR, Megson IL, Wright PG. Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta 1998, 1425:168-176.
64. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine 1989, Oxford, UK: Oxford University Press, 2.
65. Young IS, Woodside JV. Antioxidant in health and disease. J Clin Pathol 2001, 54:176-186. 10.1136/jcp.54.3.176, 11253127.
66. Berndt C, Lillig CH, Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 2007, 292:1227-1236.
67. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J 1997, 11:526-534.
68. Bader N, Grune T. Protein oxidation and proteolysis. Biol Chem 2006, 387:1351-1355. 10.1515/BC.2006.169, 17081106.
69. Jung T, Bader N, Grune T. Oxidized proteins: intracellular distribution and recognition by the proteasome. Arc Bioch Bioph 2007, 462:231-237.
70. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 2006, 27:303-314.
71. Liu H, Colavitti R, Rovira II, Finkel T. Redox-dependent transcriptional regulation. Circ Res 2005, 97:967-974. 10.1161/01.RES.0000188210.72062.10, 16284189.
72. Fritz G, Grosch S, Tomicic M, Kaina B. APE/Ref-1 and the mammalian response to genotoxic stress. Toxicology 2003, 193:67-78. 10.1016/S0300-483X(03)00290-7, 14599768.
73. Tell G, Damante G, Caldwell D, Kelley MR. The intracellular localization of APE/Ref-1: more than a passive phenomenon?. Antioxid Redox Signal 2005, 7:367-384. 10.1089/ars.2005.7.367, 15706084.
74. Shafritz DA, Oertel M, Menthena A, Nierhoff D, Dabeva MD. Liver stem cells and the prospects for liver reconstitution by transplanted cells. Hepatology 2006, 43:S89-S98. 10.1002/hep.21047, 16447292.
75. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to issue injury. J Biol Chem 2000, 275:2247-2250. 10.1074/jbc.275.4.2247, 10644669.
76. Pinzani M, Marra F. Cytokine receptor and signalling in hepatic stellate cells. Semin Liv Dis 2001, 21:397-417.
77. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 2003, 38:S28-S53.
78. Pinzani M, Rombouts K. Liver fibrosis-from the bench to clinical targets. Dig Liver Dis 2004, 36:231-242. 10.1016/j.dld.2004.01.003, 15115333.
79. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005, 115:109-118.
80. Friedman SL. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutics implications. Nat Clin Pract Gastroenterol Hepatol 2004, 1:98-105. 10.1038/ncpgasthep0055, 16265071.
81. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008, 88:125-172. 10.1152/physrev.00013.2007, 18195085.
82. Parola M, Marra F, Pinzani M. Myofibroblast-like cells and liver fibrogenesis: emerging concepts in a rapidly moving scenario. Mol Asp Med 2008, 29:58-66.
83. Medina J, Arroyo AG, Sánchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004, 39:1185-1195. 10.1002/hep.20193, 15122744.
84. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004, 40:860-867. 10.1016/j.jhep.2004.03.007, 15094237.
85. Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T. Hepatic stellate cells/myofibroblast subpopulation in fibrotic human and rat livers. J Hepatol 2002, 36:200-209. 10.1016/S0168-8278(01)00260-4, 11830331.
86. Cassiman D, Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cells research. J Hepatol 2002, 37:527-535. 10.1016/S0168-8278(02)00263-5, 12217608.
87. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004, 126:955-963. 10.1053/j.gastro.2004.02.025, 15057733.
88. Russo FP, Alison MR, Bigger BW, Amofah E, Florou A, Amin F, Bou-Gharios G, Jeffery R, Iredale JP, Forbes SJ. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006, 130:1807-1821. 10.1053/j.gastro.2006.01.036, 16697743.
89. Valfrè di Bonzo L, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, Novo E, Sanavio F, Cannito S, Zamara E, Bertero M, Davit A, Francica S, Novelli F, Colombatto S, Fagioli F, Parola M. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008, 57:223-231. 10.1136/gut.2006.111617, 17639088.
90. Forbes SJ. Stem cell therapy for chronic liver disease - choosing the right tools for the job. Gut 2008, 57:153-155. 10.1136/gut.2007.134247, 18192451.
91. Iredale J. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 2007, 117:539-548. 10.1172/JCI30542, 17332881.
92. Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzuti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005, 42:1339-1348. 10.1002/hep.20965, 16317688.
93. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cravanzola C, Compagnone A, Colombatto S, Marra F, Pinzani M, Parola M. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol 2007, 170:1942-1953. 10.2353/ajpath.2007.060887, 17525262.
94. Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Monitillo L, Cannito S, Petrai I, Mazzocca A, Bonacchi A, De Franco RS, Colombatto S, Autelli R, Pinzani M, Parola M. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006, 55:1174-1182. 10.1136/gut.2005.082701, 16423888.
95. El-Sharkawy AM, Oakley F, Mann D. The role and regulation of hepatic stellate cells apoptosis in reversal of liver fibrosis. Apoptosis 2005, 10:927-939. 10.1007/s10495-005-1055-4, 16151628.
96. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001, 2:589-598. 10.1038/35085008, 11483992.
97. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83:655-663.
98. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002, 123:1323-1330. 10.1053/gast.2002.35953, 12360492.
99. Den Hertog J, Groen A, Wijk T. Redox regulation of protein-tyrosine phosphatases. Arch Biochem Biophys 2005, 434:11-15. 10.1016/j.abb.2004.05.024, 15629103.
100. Tonks KN. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005, 121:667-670. 10.1016/j.cell.2005.05.016, 15935753.
101. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Mol Cell Biol 2006, 7:833-845.
102. Weiss FU, Daub H, Ullrich A. Novel mechanisms of RTK signal generation. Curr Opin Genet Dev 1997, 7:80-86. 10.1016/S0959-437X(97)80113-X, 9024637.
103. Gotoh Y, Cooper JA. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-α signal transduction. J Biol Chem 1998, 273:17477-17482. 10.1074/jbc.273.28.17477, 9651337.
104. Liu H, Nishitoh H, Ichijo H, Kyriakis JM. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin. Mol Cell Biol 2000, 20:2198-2208. 10.1128/MCB.20.6.2198-2208.2000, 10688666.
105. Zingg JM. Modulation of signal transduction by vitamin E. Mol Aspects Med 2007, 28:481-506. 10.1016/j.mam.2006.12.009, 17320164.
106. Schreck R, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of NFκB transcription factor and HIV-1. Trends Cell Biol 1991, 1:39-42. 10.1016/0962-8924(91)90072-H, 14731549.
107. Temkin V, Karin M. From death receptor to reactive oxygen species and c-Jun N-terminal protein kinase: the receptor-interacting protein 1 odyssey. Immunol Rev 2007, 220:8-21. 10.1111/j.1600-065X.2007.00560.x, 17979836.
108. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005, 115:2625-2632. 10.1172/JCI26322, 16200195.
109. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptative immunity. Trends Immunol 2004, 25:280-288. 10.1016/j.it.2004.03.008, 15145317.
110. Gloire G, Legrand-Poels S, Piette J. NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 72:1493-1505. 10.1016/j.bcp.2006.04.011, 16723122.
111. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004, 350:2383-2397. 10.1056/NEJMra031573, 15175440.
112. Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology 2007, 46:1291-1301. 10.1002/hep.21886, 17886335.
113. Philippe MA, Ruddell RG, Ramm GA. Role of Iron in hepatic fibrosis: one pieces in the puzzle. World J Gastroenterol 2007, 13:4746-4754.
114. Pietrangelo A. Hemochromatosis. Gut 2003, 52:ii23-ii30. 10.1136/gut.52.suppl_2.ii23, 12651879.
115. Pietrangelo A. Hemochromatosis gene modifies corse of hepatitis C viral infection. Gastroenterology 2003, 124:1509-1523. 10.1016/S0016-5085(03)00275-0, 12730889.
116. Martinelli AL, Ramalho LN, Zucoloto S. Hepatic stellate cells in hepatitis C patients: relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004, 19:91-98. 10.1111/j.1440-1746.2004.03255.x, 14675249.
117. Rigamonti C, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G, Boldorini R, Sartori M. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest 2002, 32:28-35. 10.1046/j.1365-2362.2002.0320s1028.x, 11886429.
118. Bridle K, Cheung TK, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006, 30:106-112. 10.1111/j.1530-0277.2006.00002.x, 16433737.
119. Brittenham GM. Iron chelators and iron toxicity. Alcohol 2003, 30:151-158. 10.1016/S0741-8329(03)00101-0, 12957300.
120. Pietrangelo A, Borella F, Casalgrandi G, Montosi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A. Antioxidant activity of sylibin in vivo during chronic iron overload in rats. Gastroenterology 1995, 109:1941-1949. 10.1016/0016-5085(95)90762-9, 7498660.
121. Pietrangelo A, Gualdi R, Casalgrandi G, Montosi G, Venturi E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest 1995, 95:1824-1831. 10.1172/JCI117861, 7706489.
122. Eaton JW, Qian M. Molecular bases of cellular iron toxicity. Free Radic Biol Med 2002, 32:833-840. 10.1016/S0891-5849(02)00772-4, 11978485.
123. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005, 202:199-211. 10.1016/j.taap.2004.06.021, 15629195.
124. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis 2005, 25:433-449. 10.1055/s-2005-923315, 16315137.
125. Cairo G, Recalcati S, Pietrangelo A, Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 2002, 32:1237-1243. 10.1016/S0891-5849(02)00825-0, 12057761.
126. Llanos RM, Mercer JF. The molecular basis of copper homeostasis in copper-related disorders. DNA Cell Biol 2002, 21:259-270. 10.1089/104454902753759681, 12042066.
127. Tao TY, Gitlin JD. Hepatic copper metabolism: insights from genetic disease. Hepatology 2003, 37:1241-1247. 10.1053/jhep.2003.50281, 12773998.
128. Sokol RJ, Winklhofer-Roob BM, Deveraux MW, McKim JM. Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology 1995, 109:1249-1256. 10.1016/0016-5085(95)90585-5, 7557092.
129. Novo E, Zamara E, Valfre di Bonzo L, Parola M. Modulation of cell death, signal transduction and cell response by oxidative stress in the progression of chronic liver diseases. Liver Cirrhosis Research Hauppauge, NY: Nova Science Publishers, Burns JL, .
130. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int 2006, 26:1021-1028. 10.1111/j.1478-3231.2006.01323.x, 17032401.
131. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000, 32:98-112. 10.1016/S0168-8278(00)80419-5, 10728798.
132. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchinson J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:764-767. 10.1016/S0168-8278(01)00055-1, 11434626.
133. Arteel GE. Oxidant and antioxidant in alcohol-induced liver disease. Gastroenterology 2003, 124:778-790. 10.1053/gast.2003.50087, 12612915.
134. Nanji AA. Role of different dietary fatty acids in the pathogenesis of experimental alcoholic liver disease. Alcohol 2004, 34:21-25. 10.1016/j.alcohol.2004.08.005, 15670661.
135. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 2008, 29:9-16. 10.1016/j.mam.2007.09.004, 18045675.
136. Dey A, Cederbaum AI. Alcohol and oxidative liver injury. Hepatology 2006, 43:S63-S74. 10.1002/hep.20957, 16447273.
137. Parola M, Robino G, Bordone R, Leonarduzzi G, Casini A, Pinzani M, Neve E, Bellomo G, Dianzani MU, Ingelman-Sundberg M, Albano E. Detection of cytochrome P450A (CYP3A) in human hepatic stellate cells. Biochem Biophys Res Commun 1997, 238:420-424. 10.1006/bbrc.1997.7307, 9299524.
138. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005, 42:5-13. 10.1002/hep.20750, 15962320.
139. Pessayre D, Fromenty B. NASH: a mithocondrial disease. J Hepatol 2005, 42:928-940. 10.1016/j.jhep.2005.03.004, 15885365.
140. Pan M, Cederbaum AI, Zhang YL, Ginsberg HN, Williams KJ, Fisher EA. Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest 2004, 113:1277-1287.
141. Bardag-Gorce F, French BA, Nan L, Song H, Nguyen SK, Yong H, Dede J, French SW. CYP2E1 induced by ethanol causes oxidative stress, proteasome inhibition and cytokeratin aggresome (Mallory body-like) formation. Exp Mol Pathol 2006, 81:191-201. 10.1016/j.yexmp.2006.07.007, 17034788.
142. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231. 10.1056/NEJMra011775, 11961152.
143. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007, 132:2191-2207. 10.1053/j.gastro.2007.03.055, 17498512.
144. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic sindrome. Hepatology 2003, 38:536.
145. Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945. 10.1053/j.gastro.2006.05.054, 16952562.
146. Day CP, James OF. Steatohepatitis: a tale of two 'hits'?. Gastroenterology 1998, 114:842-845. 10.1016/S0016-5085(98)70599-2, 9547102.
147. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48:634-642. 10.1007/s00125-005-1682-x, 15747110.
148. Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723. 10.1053/gast.2001.27126, 11522755.
149. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol 2001, 281:G1135-1139.
150. Mehta K, Van Thiel DH, Shah N, Mobarhan S. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Nutr Rev 2002, 60:289-293. 10.1301/002966402320387224, 12296456.
151. Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going?. Gut 2002, 50:585-588. 10.1136/gut.50.5.585, 11950797.
152. Leclerq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non alcoholic steatohepatitis. J Clin Invest 2000, 105:1067-1075. 10.1172/JCI8814, 10772651.
153. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133. 10.1002/hep.510270121, 9425928.
154. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004, 114:147-152.
155. Serviddio G, Sastre J, Bellanti F, Vina J, Vendemmiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Asp Med 2008, 29:22-35.
156. Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol 2006, 21:S56-S60. 10.1111/j.1440-1746.2006.04582.x, 16958674.
157. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a casual role in multiple forms of insulin resistance. Nature 2006, 440:944-948. 10.1038/nature04634, 16612386.
158. Bloch-Damti A, Basham N. Proposed mechanisms for the induction of insulin resistance by oxidative stress. Antioxid Redox Signal 2005, 7:1553-1567. 10.1089/ars.2005.7.1553, 16356119.
159. Shattemberg JM, Wang Y, Singh R, Rigoli RM, Czaja MJ. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signalling. J Biol Chem 2005, 280:9887-9894. 10.1074/jbc.M410310200, 15632182.
160. Xu Z, Chen L, Leung L, Yen TSB, Lee C, Chan JY. Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 2005, 102:4120-4125. 10.1073/pnas.0500660102, 15738389.
161. Parola M, Novo E. Nrf1 gene expression in the liver: a single gene linking oxidative stress to NAFLD, NASH and hepatic tumours. J Hepatol 2005, 43:1096-1097. 10.1016/j.jhep.2005.09.008, 16239046.
162. Loguercio C, Federico A. Oxidative stress in viral and alcoholis hepatitis. Free Radic Biol Med 2003, 34:1-10. 10.1016/S0891-5849(02)01167-X, 12498974.
163. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyosh H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001, 61:4365-4370.
164. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375. 10.1053/gast.2002.30983, 11832451.
165. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, Okuda M, Gosert R, Xiao SY, Weinman SA, Lemon SM. Steatosis and liver cancer in transgenic mice expressing the structural and non-structural proteins of hepatitis C virus. Gastroenterology 2002, 122:352-365. 10.1053/gast.2002.31001, 11832450.
166. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001, 98:9599-604. 10.1073/pnas.171311298, 11481452.
167. Qadri I, Iwahashi M, Capasso JM, Hopkin MW, Flores S, Schaack J, Simon FR. Induced oxidative stress and activated expression of manganese superoxide dismutase (MnSOD) during hepatitis C virus replication: Role of JNK, p38MAPK AP-1. Biochem J 2004, 378:919-928. 10.1042/BJ20031587, 14670077.
168. Waris G, Livolsi A, Imbert V, Peyron JF, Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkBα and its degradation by calpain protease. J Biol Chem 2003, 278:40778-40787. 10.1074/jbc.M303248200, 12909638.
169. Seronello S, Sheikh MY, Choi J. Redox regulation of hepatitis C in nonalcoholic and alcoholic liver. Free Rad Biol Med 2007, 43:869-882. 10.1016/j.freeradbiomed.2007.05.036, 17697932.
170. Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008, 134:226-238. 10.1053/j.gastro.2007.10.011, 18166355.
171. Alpini G, McGill JM, La Russo NF. The pathobiology of biliary epithelia. Hepatology 2002, 35:1256-1268. 10.1053/jhep.2002.33541, 11981776.
172. Xia X, Demorrow S, Francis H, Glaser S, Alpini G, Marzioni M, Fava G, Lesage G. Cholangiocyte injury and ductopenic syndromes. Semin Liver Dis 2007, 27:401-12. 10.1055/s-2007-991516, 17979076.
173. Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, Marra F, Herbst H, Alpini G, Milani S. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 1999, 31:100-109. 10.1016/S0168-8278(99)80169-X, 10424289.
174. Parola M, Leonarduzzi G, Robino G, Albano E, Poli G, Dianzani MU. On the role of lipid peroxidation in the pathogenesis of liver damage induced by long-standing cholestasis. Free Radic Biol Med 1996, 20:351-359. 10.1016/0891-5849(96)02055-2, 8720905.
175. Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H, Wakasa K. In situ detection of oxidative DNA damage, 8-hydroxy-deoxyguanosine, in chronic human liver disease. J Hepatol 2001, 35:613-618. 10.1016/S0168-8278(01)00171-4, 11690707.
176. Tsuneyama K, Harada K, Kono N, Sasaki M, Saito T, Gershwin ME, Ikemoto M, Aria H, Nakanuma Y. Damaged interlobular bile ducts in primary biliary cirrhosis show reduced expression of glutathione-S-transferase-pi and aberrant expression of 4-hydroxynonenal. J Hepatol 2002, 37:176-183. 10.1016/S0168-8278(02)00105-8, 12127421.
177. Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta 2003, 1637:142-150.
178. Salunga TL, Cui ZG, Shimoda S, Zheng HC, Nomato K, Kondo T, Takano Y, Selmi C, Alpini G, Gershwin ME, Tsuneyama K. Oxidative-stress-induced apoptosis of bile duct cells in primary biliary cirrhosis. J Autoimmun 2007, 29:78-86. 10.1016/j.jaut.2007.04.002, 17544621.
179. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001, 33:616-626. 10.1053/jhep.2001.22702, 11230742.
180. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998, 4:165-178. 10.1007/s0089480040165, 9562975.
181. Rodrigues CM, Fan G, Ma X, Kren BT, Steer CJ. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-2799. 10.1172/JCI1325, 9637713.
182. Gumpricht E, Dahl R, Yerushalmi B, Devereaux MW, Sokol RJ. Nitric oxide ameliorates hydrophobic bile acid-induced apoptosis in isolated rat hepatocytes by non-mitochondrial pathways. J Biol Chem 2002, 277:25823-25830. 10.1074/jbc.M112305200, 12006578.
183. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003, 37:493-503. 10.1053/jhep.2003.50127, 12601343.
184. Kaplowitz N. Mechanisms of liver cell injury. J Hepatol 2000, 32:39-47. 10.1016/S0168-8278(00)80414-6, 10728793.
185. Jaeschke H, Gore GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002, 65:166-176. 10.1093/toxsci/65.2.166, 11812920.
186. Mahli H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths?. Hepatology 2006, 43:S31-44. 10.1002/hep.21062, 16447272.
187. Kaplowitz N. Liver biology and pathobiology. Hepatology 2006, 44:282.
188. Arnaiz SL, Llesuy S, Cutrin JC, Boveris A. Oxidative stress by acute acetominophen administration in mouse liver. Free Radic Biol Med 1995, 19:303-310. 10.1016/0891-5849(95)00023-Q, 7557544.
189. Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, Parola M. 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol 2004, 40:60-68. 10.1016/S0168-8278(03)00480-X, 14672615.
190. Patel T, Bronk SF, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest 1994, 94:2183-2192. 10.1172/JCI117579, 7989573.
191. Parola M, Robino G, Dianzani MU. 4-Hydroxy-2,3-alkenals as molecular mediators of oxidative stress in the pathogenesis of liver fibrosis. Int J Mol Med 1999, 4:425-432.
192. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005, 54:1024-1033. 10.1136/gut.2004.053850, 15951554.
193. Festjens N, Vanden Berghe T, Vandenabeele P. Necrosis, a well-orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 2006, 1757:1371-1387. 10.1016/j.bbabio.2006.06.014, 16950166.
194. Festjens N, Vanden Berghe T, Cornelis S, Vandenabeele P. RIP1, a kinase on the crossroads of a cell's decision to live or die. Cell Death Diff 2007, 14:400-410.
195. Vanden Berghe T, Declercq W, Vandenabeele P. NADPH oxidases: new players in TNF-induced necrotic cell death. Mol Cell 2007, 26:769-771. 10.1016/j.molcel.2007.06.002, 17588511.
196. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004, 305:626-629. 10.1126/science.1099320, 15286356.
197. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003, 114:181-190. 10.1016/S0092-8674(03)00521-X, 12887920.
198. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40. 10.1038/35065000, 11242034.
199. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, Karin M. The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006, 124:601-613. 10.1016/j.cell.2006.01.021, 16469705.
200. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schröter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997, 386:517-521. 10.1038/386517a0, 9087414.
201. Ding WX, Ni HM, DiFrancesca D, Stolz DB, Yin XM. Bid-dependent generation of oxigen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology 2004, 40:403-413. 10.1002/hep.20310, 15368445.
202. Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-Induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007, 26:675-687. 10.1016/j.molcel.2007.04.021, 17560373.
203. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005, 120:649-661. 10.1016/j.cell.2004.12.041, 15766528.
204. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542. 10.1016/j.cell.2004.10.017, 15537542.
205. Tobiume K, Matsuzawa A, Takahashi T, Nishitoh H, Morita K, Takeda K, Minowa O, Miyazono K, Noda T, Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2001, 2:222-228. 10.1093/embo-reports/kve046, 11266364.
206. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 2002, 90:1259-1266. 10.1161/01.RES.0000022160.64355.62, 12089063.
207. Miramar MD, Costantini P, Ravagnan L, Saraiva LM, Haouzi D, Brothers G, Penninger JM, Peleato ML, Kroemer G, Susin SA. NADPH oxidase activity of mitochondrial apoptosis-inducing factor. J Biol Chem 2001, 276:16391-16398. 10.1074/jbc.M010498200, 11278689.
208. Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol 2004, 36:1303-1316.
209. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003, 115:61-70. 10.1016/S0092-8674(03)00757-8, 14532003.
210. Jones PL, Ping D, Boss JM. Tumor necrosis factor alpha and interleukin-1beta regulate the murine manganese superoxide dismutase gene through a complex intronic enhancer involving C/EPB-beta and NF-kappaB. Mol Cell Biol 1997, 17:6970-6981.
211. Lin H, Chan R, Lo M, Czaja MJ. NF-κB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. Hepatology 2002, 35:772-778. 10.1053/jhep.2002.32534, 11915022.
212. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Sem Cell Dev Biol 2007, 18:716-731.
213. Marciniak SJ, Ron D. Endoplasmic reticulum stress signaling in disease. Physiol Rev 2006, 86:1133-1149. 10.1152/physrev.00015.2006, 17015486.
214. Wei Y, Wang D, Topczewski F, Pagliassotti MJ. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am J Physiol Endocrinol Metab 2006, 291:E275-E281. 10.1152/ajpendo.00644.2005, 16492686.
215. Benali-Furet N, Chami M, Ludivine H, DeGiorgi F, Vernejoul F, Lagorce D, Buscail L, Bartenschlager R, Ichas F, Rizzuto R, Paterlini-Brechot P. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and calcium depletion. Oncogene 2005, 24:4921-4933. 10.1038/sj.onc.1208673, 15897896.
216. Chan SW, Egan PA. Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. FASEB J 2005, 19:1510-1512.
217. Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Venditelli F, Costantino A, Geraci A, Rapicetta M. Activation of the ER stress gene GADD153 by hepatitis C virus sensitized cells to oxidant injury. Virus Res 2007, 126:128-138. 10.1016/j.virusres.2007.02.006, 17368854.
218. Christen V, Treves S, Duong FH, Heim MH. Activation of endoplasmic reticulum stress response by hepatitis viruses up-regulates protein phosphatases 2A. Hepatology 2007, 46:558-565. 10.1002/hep.21611, 17526027.
219. Kaplowitz N, Ji C. Unfolding new mechanisms of alcoholic liver disease in the endoplasmic reticulum. J Gastroenterol Hepatol 2006, 21:S7-9. 10.1111/j.1440-1746.2006.04581.x, 16958678.
220. Ji C, Kaplowitz N. ER stress: can the liver cope?. J Hepatol 2006, 45:321-333. 10.1016/j.jhep.2006.06.004, 16797772.
221. Kaplowitz N, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. Sem Liv Dis 2007, 27:367-377.
222. Yip WW, Burt AD. Alcoholic liver disease. Semin Diagn Pathol 2006, 23:149-160. 10.1053/j.semdp.2006.11.002, 17355088.
223. Bailey SM, Cunningham CC. Contribution of mitochondria to oxidative stress associated with alcohol liver disease. Free Rad Biol Med 2002, 32:11-16. 10.1016/S0891-5849(01)00769-9, 11755312.
224. Fernandez-Checa JC, Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol 2005, 204:263-273. 10.1016/j.taap.2004.10.001, 15845418.
225. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002, 122:2049-2063. 10.1053/gast.2002.33613, 12055609.
226. Mansouri A, Fromenty B, Berson A, Robin MA, Grimbert S, Beaugrand M, Erlinger S, Pessayre D. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholics. J Hepatol 1997, 27:96-102. 10.1016/S0168-8278(97)80286-3, 9252080.
227. Adachi M, Higuchi H, Miura S, Azuma T, Inokuchi S, Saito H, Kato S, Ishii H. Bax interacts with voltage-dependent anion channel and mediates ethanol-induced apoptosis in rat hepatocytes. Am J Physiol 2004, 287:G695-G705.
228. Adachi M, Ishii H. Role of mitochondria in alcoholic liver injury. Free Rad Biol Med 2002, 32:487-491. 10.1016/S0891-5849(02)00740-2, 11958949.
229. Caro AA, Cederbaum AI. Oxidative stress, toxicology and pharmacology of CYP2E1. Ann Rev Pharmacol Toxicol 2004, 44:27-42.
230. Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997, 26(Suppl 2):43-53. 10.1016/S0168-8278(97)80496-5, 9204409.
231. Hines IN, Wheeler MD. Recent advances in alcoholic liver disease. III. Role of the innate immune response in alcoholic hepatitis. Am J Physiol 2004, 287:G310-G314.
232. Hoek JB, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Semin Liver Dis 2004, 24:257-272. 10.1055/s-2004-832939, 15349804.
233. Shulga N, Hoek JB, Pastorino JG. Elevated PTEN levels account for the increased sensitivity of ethanol-exposed cells to tumor necrosis factor cytotoxicity. J Biol Chem 2005, 280:9416-9424. 10.1074/jbc.M409505200, 15623531.
234. Sampey BP, Stewart BJ, Petersen DR. Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase 1/2 activity via 4-hydroxynonenal. J Biol Chem 2007, 282:1925-1937. 10.1074/jbc.M610602200, 17107949.
235. Li J, Billiar TR. Nitric oxide. IV. Determinants of nitric oxide protection and toxicity in liver. Am J Physiol 1998, 276:G1069-G1073.
236. Clemens MG. Nitric oxide in liver injury. Hepatology 1999, 30:1-5. 10.1002/hep.510300148, 10385631.
237. Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol Chem 2002, 383:411-423. 10.1515/BC.2002.045, 12033432.
238. Kim PKM, Zuckerbraun BS, Otterbein LE, Vodovotz Y, Billiar TR. Till cell death do us part: nitric oxide and mechanisms of hepatotoxicity. Biol Chem 2004, 385:11-15. 10.1515/BC.2004.002, 14977041.
239. Vodovotz Y, Kim PKM, Bagci EZ, Ermentrout GB, Chow CC, Bahar I, Billiar TR. Inflammatory modulation of hepatocytes apoptosis by nitric oxide: in vivo, in vitro, and in silico studies. Curr Mol Med 2004, 4:753-762. 10.2174/1566524043359944, 15579022.
240. Grisham MB, Jourd'Heuil D, Wink DA. Nitric oxide. I. Physiological chemistry of nitric oxide and its metabolites: implication in inflammation. Am J Physiol 1998, 278:G315-G321.
241. Shash V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann RJ, Sessa WC. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997, 100:2923-2930. 10.1172/JCI119842, 9389760.
242. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semis Liver Dis 2001, 21:337-349.
243. Rao RK, Seth A, Sheth P. Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol 2004, 286:G881-G884.
244. Iredale JP. Hepatic stellate cell behaviour during resolution of liver injury. Semin Liver Dis 2001, 21:427-436. 10.1055/s-2001-17557, 11586470.
245. Robino G, Parola M, Marra F, Caligiuri A, De Franco RM, Zamara E, Bellomo G, Gentilini P, Pinzani M, Dianzani MU. Interaction between 4-hydroxy-2,3-alkenals and the platelet-derived growth factor-beta receptor. Reduced tyrosine phosphorylation and downstream signaling in hepatic stellate cells. J Biol Chem 2000, 275:40561-40567. 10.1074/jbc.M007694200, 11007794.
246. Novo E, Marra F, Zamara E, Valfrè di Bonzo L, Caligiuri A, Cannito S, Antonaci C, Colombatto S, Pinzani M, Parola M. Dose dependent and divergent effects of superoxide anion on cell death, proliferation, and migration of activated human hepatic stellate cells. Gut 2006, 55:90-97. 10.1136/gut.2005.069633, 16041064.
247. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?. Antioxid Redox Signal 2007, 9:2277-2293. 10.1089/ars.2007.1782, 17979528.
248. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. J Mol Med 2007, 14:72-81.
249. Vidali M, Stewart FS, Albano E. Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. Trends Mol Med 2008, 14:63-71. 10.1016/j.molmed.2007.12.005, 18222109.
250. Isayama F, Hines IN, Kremer M, Milton RJ, Byrd CL, Perry AW, McKim SE, Parsons C, Rippe RA, Wheeler MD. LPS signaling enhances hepatic fibrogenesis caused by experimental cholestasis in mice. Am J Physiol 2006, 290:G1318-G1328.
251. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Rad Biol Med 2007, 42:153-164. 10.1016/j.freeradbiomed.2006.09.030, 17189821.
252. Forman HJ, Torres M. Redox signaling in macrophages. Mol Asp Med 2001, 22:89-216.
253. Thakur V, McMullen MR, Pritchard MT, Nagy LE. Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol 2007, 22:S53-S56. 10.1111/j.1440-1746.2006.04650.x, 17567466.
254. Salmon J, Millard SS, Brogle NL, Kimberly RP. Fc gamma receptor IIIb enhances Fc gamma receptor Ila function in an oxidant-dependent and allele-sensitive manner. J Clin Invest 1995, 95:2877-2885. 10.1172/JCI117994, 7769129.
255. Greenberg S, Chang P, Silverstein SC. Tyrosine phosphorylation of the gamma subunit of Fc gamma receptors, p72syk, and paxillin during Fc receptor-mediated phagocytosis in macrophages. J Biol Chem 1994, 269:3897-3902.
256. Holmes N. CD45: all is not yet crystal clear. Immunology 2006, 117:145-155. 10.1111/j.1365-2567.2005.02265.x, 16423050.
257. Lee K, Esselman WJ. Inhibition of PTPs by H2O2 regulates the activation of distinct MAPK pathways. Free Radic Biol Med 2002, 33:1121-1132. 10.1016/S0891-5849(02)01000-6, 12374624.
258. Harvath L, Balke JA, Christiansen NP, Russell AA, Skubitz KM. Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. J Immunol 1991, 146:949-957.
259. Hoffmeyer F, Witte K, Gebhardt U, Schmidt RE. The low affinity Fc gamma RIIa and Fc gamma RIIIb on polymorphonuclear neutrophil are differentially regulated by CD45 phosphatase. J Immunol 1995, 155:4016-4023.
260. Fialkow L, Chan CK, Downey GP. Inhibition of CD45 during neutrophil activation. J Immunol 1997, 158:5409-5417.
261. Yasui K, Kobayashi N, Yamazaki T, Agematsu K, Matsuzaki S, Ito S, Nakata S, Baba A, Koike K. Superoxide dismutase (SOD) as a potential inhibitory mediator of inflammation via neutrophil apoptosis. Free Radic Res 2005, 39:755-762. 10.1080/10715760500104066, 16036355.
262. Melley DD, Evans TW, Quinlan GJ. Redox regulation of neutrophil apoptosis and the systemic inflammatory response syndrome. Clin Sci (London) 2005, 108:413-424.
263. Zhang B, Hirahashi J, Cullere X, Mayadas TN. Elucidation of molecular events leading to neutrophil apoptosis following phagocytosis: cross-talk between caspase 8, reactive oxygen species, and MAPK/ERK activation. J Biol Chem 2003, 278:28443-28454. 10.1074/jbc.M210727200, 12736263.
264. Fortin M, Steff AM, Felberg J, Ding I, Schraven B, Johnson P, Hugo P. Apoptosis mediated trough CD45 is independent of its phosphatase activity and association with leukocyte phosphatase-associated phosphoprotein. J Immunol 2002, 168:6084-6609.
265. Gardai S, Whitlock BB, Helgason C, Ambruso D, Fadok V, Bratton D, Henson PM. Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem 2002, 277:5236-5246. 10.1074/jbc.M110005200, 11724799.
266. Blaylock MG, Cuthbertson BH, Galley HF, Ferguson NR, Webster NR. The effect of nitric oxide and peroxynitrite on apoptosis in human polynorphonuclear leukocytes. Free Radic Biol Med 1998, 25:748-752. 10.1016/S0891-5849(98)00108-7, 9801076.
267. Ward C, Wong TH, Murray J, Rahman I, Haslett C, Chilvers ER, Rossi AG. Induction of human neutrophil apoptosis by nitric oxide donors: evidence for caspase-dependent, cyclic-GMP-independent, mechanism. Biochem Pharmacol 2000, 59:305-314. 10.1016/S0006-2952(99)00329-9, 10609560.
268. Natarajan V, Taher MM, Roehm B, Parinandi NL, Schmid HH, Kiss Z, Garcia JG. Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty liver hydroperoxide. J Biol Chem 1993, 268:930-937.
269. Patel KD, Zimmerman GA, Prescott SM, McEver RP, McIntyre TM. Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol 1991, 112:749-759. 10.1083/jcb.112.4.749, 1704376.
270. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates trasforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997, 11:851-857.
271. Parola M, Leonarduzzi G, Biasi F, Albano E, Biocca ME, Poli G, Dianzani MU. Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and chirrosis. Hepatology 1992, 16:1014-1021. 10.1002/hep.1840160426, 1398481.
272. Parola M, Muraca R, Dianzani I, Barrera G, Leonarduzzi G, Bendinelli P, Piccoletti R, Poli G. Vitamin E dietary supplementation inhibits trasforming growth factor β1 gene expression in the rat liver. FEBS Lett 1992, 308:266-270.
273. Marra F, DeFranco R, Grappone C, Parola M, Milani S, Leonarduzzi G, Pastacaldi S, Wenzel UO, Pinzani M, Dianzani MU, Laffi G, Gentilini P. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 1999, 47:66-75.
274. Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, Mastrocola R, Novo E, Bertolani C, Milani S, Vizzutti F, Vercelli A, Pinzani M, Laffi G, LaVilla G, Parola M, Marra F. Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 2007, 46:230-238. 10.1016/j.jhep.2006.09.007, 17125873.
275. Valente AJ, Graves DT, Vialle-Valentin CE, Delgado R, Schwartz CJ. Purification of a monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry 1988, 27:4162-4168. 10.1021/bi00411a039, 3415979.
276. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes. FASEB J 1994, 8:1055-1060.
277. Rollins BJ. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996, 2:198-204. 10.1016/1357-4310(96)88772-7, 8796888.
278. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, Flavell R, Glaude R, Rollins B. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 1997, 62:577-580.
279. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002, 160:91-102. 10.1016/S0021-9150(01)00571-8, 11755926.
280. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptative immunity: therapeutic opportunities and controversies. Microcirculation 2003, 10:247-257.
281. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858-866. 10.1161/01.RES.0000146672.10582.17, 15514167.
282. Marra F, Valente AJ, Pinzani M, Abboud HE. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1. Regulation by proinflammatory cytokines. J Clin Invest 1993, 92:1674-1680. 10.1172/JCI116753, 8408620.
283. Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y. Monocyte chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and human liver disease. J Leukocyte Biol 1994, 55:120-126.
284. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, Romanelli RG, Laffi G, Gentilini P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998, 152:423-430.
285. Marra F, Valente AJ, Grandaliano G, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1. Hepatology 1995, 22:780-787.
286. Xu Y, Rojkind M, Czaja MJ. Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. Gastroenterology 1996, 110:1870-1877. 10.1053/gast.1996.v110.pm8964413, 8964413.
287. Roebuck KA, Carpenter LR, Lakshminarayanan V, Page SM, Moy JN, Thomas LL. Stimulus-specific regulation of chemokine expression involves differential activation of the redox-responsive transcription factors AP-1 and NF-kappaB. J Leukoc Biol 1999, 65:291-298.
288. Parola M, Robino G, Marra F, Pinzani M, Bellomo G, Leonarduzzi G, Chiarugi P, Camandola S, Poli G, Waeg G, Gentilini P, Dianzani MU. HNE interacts directly with JNK isoforms in human hepatic stellate cells. J Clin Invest 1998, 102:1942-1950. 10.1172/JCI1413, 9835619.
289. Marinari UM, Nitti M, Pronzato MA, Domenicotti C. Role of PKC-dependent pathways in HNE-induced cell protein transport and secretion. Mol Asp Med 2003, 24:205-211.
290. Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, Laffi G, Montalto P, Gentilini P. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999, 29:140-148. 10.1002/hep.510290107, 9862860.
291. Mourelle M, Muriel P, Favari L, Franco T. Prevention of CCl4-induced liver cirrhosis by silymarin. Fundam Clin Pharmacol 1989, 3:183-191.
292. Boigk G, Stroedter L, Herbst H, Waldschmidt J, Riecken EO, Schuppan D. Silymarin retard collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997, 26:643-649. 10.1002/hep.510260316, 9303494.
293. Gasso M, Rubio M, Varala G, Cabre M, Cavalleria J, Alonso E, Deulofem R, Camps, Gimenez A, Pajares M, Pares A, Mato JM, Rodes J. Effects of S-adenosylmethionine of lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol 1996, 25:200-205. 10.1016/S0168-8278(96)80074-2, 8878782.
294. Bedossa P, Houglum K, Trautwein C, Holstege A, Chojkier M. Stimulation of collagen α 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury. A link to tissue fibrosis?. Hepatology 1994, 19:1262-1271.
295. Houglum K, Bedossa P, Chojkier M. TGF-α and collagen α 1(I) gene expression are increased in hepatic acinar zone I of rats with iron overload. Am J Physiol 1994, 267:G908-G913.
296. Niemela O, Parkkila S, Yla-Herttuala S, Villanueva J, Ruebner B, Halsted CH. Sequential acetaldehyde production, lipid peroxidation and fibrogenesis in micropig model of alcohol induced disease. Hepatology 1995, 22:1208-1214. 10.1016/0270-9139(95)90630-4, 7557872.
297. Tsukamoto H, Horne W, Kamimura S, Niemela O, Parkkila S, Yla-Herttuala S, Brittenham GM. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest 1995, 96:620-630. 10.1172/JCI118077, 7615836.
298. Nanjii AA, Greenberg SS, Tahan SR, Fogt F, Loscalzo J, Sadrzadeh SM, Xie J, Stamler JS. Nitric oxide production in experimental alcoholic liver disease in the rat: role in protection from injury. Gastroenterology 1995, 109:899-907. 10.1016/0016-5085(95)90400-X, 7657120.
299. Muriel P. Nitric oxide protection of rat liver from lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 1998, 56:773-779. 10.1016/S0006-2952(98)00220-2, 9751083.
300. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, Gentilini P, Dianzani MU. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α 1(I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993, 194:1044-1050. 10.1006/bbrc.1993.1927, 8352762.
301. Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, Surrenti C. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997, 25:361-367. 10.1002/hep.510250218, 9021948.
302. Maher JJ, Tzagarakis C, Gimenez A. Malondialdehyde stimulates collagen production by hepatic lipocytes only upon activation in primary culture. Alcohol Alcohol 1994, 29:605-610.
303. Parola M, Pinzani M, Casini A, Leonarduzzi G, Marra F, Caligiuri A, Ceni E, Biondi P, Poli G, Dianzani MU. Induction of procollagen type I gene expression and synthesis in human hepatic stellate cells by 4-hydroxy-2,3-nonenal and other 4-hydroxy-2,3-alkenalks is related to their molecular structure. Biochem Biophys Res Commun 1996, 222:261-264. 10.1006/bbrc.1996.0732, 8670193.
304. Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, Di Sario A, Salzano R, Ridolfi F, Saccomanno S, Jezequel AM, Benedetti A. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 1998, 27:720-726. 10.1002/hep.510270313, 9500700.
305. Garcia-Trevijano E, Iraburu MJ, Fontana L, Dominguez-Rosales JA, Auster A, Covarrubias-Pinedo A, Rojkind M. Trasforming growth factor β1 induces the expression of α (I) procollagen mRNA by a hydrogen peroxide-C/EBPβ-dependent mechanism in rat hepatic stellate cells. Hepatology 1999, 29:960-970. 10.1002/hep.510290346, 10051504.
306. Nieto N, Friedman SL, Cederbaum AI. Cytochrome P502E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 2002, 277:9853-9864. 10.1074/jbc.M110506200, 11782477.
307. Nieto N, Cederbaum AI. Increased Sp1-dependent transactivation of the LAMã promoter in hepatic stellate cells co-cultured with HepG2 cells overexpressing cytochrome P450 2E1. J Biol Chem 2003, 278:15360-15372. 10.1074/jbc.M206790200, 12529372.
308. Comporti M, Arezzini B, Signorini C, Sgherri C, Monaco B, Gardi C. F2-isoprostanes stimulate collagen synthesis in activated hepatic stellate cells: a link with liver fibrosis?. Lab Invest 2005, 85:1381-1391. 10.1038/labinvest.3700332, 16127424.
309. Chen A, Davis BH. UV irradiation activates JNK and increases alpha (I) collagen gene expression in rat hepatic stellate cells. J Biol Chem 1999, 274:158-164. 10.1074/jbc.274.1.158, 9867824.
310. Nieto N, Friedman SL, Greenwel P, Cederbaum AI. Cyp2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells. Hepatology 1999, 30:987-996. 10.1002/hep.510300433, 10498651.
311. Nieto N, Greenwel P, Friedman SL, Zhang F, Dannenberg AJ, Cederbaum AI. Ethanol and arachidonic acid increase α 2 (I) collagen expression in rat hepatic stellate cells overexpressing cytochrome P450 2E1. J Biol Chem 2000, 26:20136-20145.
312. De Bleser PJ, Xu G, Rombouts K, Rogiers V, Geerts A. Glutathione levels discriminate between oxidative stress and transforming growth factor-β signalling in activated rat hepatic stellate cells. J Biol Chem 1999, 274:33881-33887. 10.1074/jbc.274.48.33881, 10567349.
313. Cao Q, Mak KM, Lieber CS. DLPC decreases TGFβ1 - induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002, 28:G1051-G1061.
314. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of Kupffer cells on stellate cells. Hepatology 2006, 44:1487-1501. 10.1002/hep.21427, 17133487.
315. Greenwel P, Dominguez-Rosales JA, Mavi G, Rivas-Estilla AM, Rojkind M. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology 2000, 31:109-116. 10.1002/hep.510310118, 10613735.
316. Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, Ramirez F, Rojkind M. Early response of alpha2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-beta independent. Hepatology 2005, 42:343-352. 10.1002/hep.20798, 16025520.
317. Chen A, Davis BH. The DNA binding protein BTEB mediates acetaldehyde-induced, Jun N-terminal kinase-dependent alphaI(I) collagen gene expression in rat hepatic stellate cells. Mol Cell Biol 2000, 20:2818-2826. 10.1128/MCB.20.8.2818-2826.2000, 10733585.
318. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. Hepatology 2004, 40:263-265. 10.1002/hep.20296, 15239111.
319. Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, Rippe RA. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol 2003, 285:G642-G651.
320. Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solè M, Colmenero J, Nicolàs JM, Jimènez W, Weich N, Gutièrrez-Ramos JC, Arroyo V, Rodès J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 2003, 125:117-125. 10.1016/S0016-5085(03)00695-4, 12851877.
321. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890-898. 10.1172/JCI1112, 9466984.
322. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, Torok NJ. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006, 43:435-443. 10.1002/hep.21093, 16496318.
323. Buck M, Kim DJ, Houglum K, Hassanein T, Chojkier M. C-Myb modulates transcription of the α-smooth muscle actin gene in activated hepatic stellate cells. Am J Physiol 2000, 278:G321-G328.
324. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002, 35:62-73. 10.1053/jhep.2002.30362, 11786960.
325. Kawada N, Seki S, Inoue M, Kuroki T. Effect of antioxidants, resveratrol, quercetin and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998, 27:1265-1274. 10.1002/hep.510270512, 9581680.
326. Svegliati-Baroni G, Di Sario A, Casini A, Ferretti G, D'Ambrosio L, Ridolfi F, Bolognini L, Salzano R, Orlandi F, Benedetti A. The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. J Hepatol 1999, 30:868-875. 10.1016/S0168-8278(99)80141-X, 10365814.
327. Reeves HL, Dach CL, Peak M, Burt AD, Day CP. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol 2000, 32:465-472. 10.1016/S0168-8278(00)80398-0, 10735617.
328. Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P, Tonnini C, D'Ambrosio L, Feliciangeli G, Macarri G, Svegliati-Baroni G. Inhibition of the Na+/H+ exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology 2001, 120:545-556. 10.1053/gast.2001.21203, 11159895.
329. Kim YK, Rhim TY, Choi I, Kim SS. N-Acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001, 276:40591-40598. 10.1074/jbc.M100975200, 11509553.
330. Adachi T, Togashi H, Suzuki A, Kasai S, Ito J, Sugahara K, Kawata S. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 2005, 41:1272-1281. 10.1002/hep.20719, 15915457.
331. Robino G, Zamara E, Novo E, Dianzani MU, Parola M. 4-Hydroxy-2,3-alkenals as signal molecules modulating proliferative and adaptative cell responses. Biofactors 2001, 15:103-106.
332. Uchida K, Shiraichi M, Naito Y, Torii Y, Nakamura Y, Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. 4-Hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem 1999, 274:2234-2242. 10.1074/jbc.274.4.2234, 9890986.
333. Oleynyk JK, Khan NA, Ramm GA, Brown KE, O'Neill R, Britton RS, Bacon BR. Aldehydic products of lipid peroxidation do not directly activate rat hepatic stellate cells. J Gastroenterol Hepatol 2002, 17:785-790. 10.1046/j.1440-1746.2002.02798.x, 12121509.
334. Whalen R, Rockey DC, Friedman SL, Boyer TD. Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Hepatology 1999, 30:927-933. 10.1002/hep.510300404, 10498644.
335. Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005, 41:1074-1084. 10.1002/hep.20683, 15841469.
336. Novo E, Cannito S, Zamara E, Valfrè di Bonzo L, Tamagno E, Colombatto S, Marra F, Pinzani M, Parola M. Cytokine-induced migration of human hepatic stellate cells requires activation of c-Jun N-terminal kinase and intracellular generation of reactive oxygen species. Gut 2007, 56:A62.
337. Failli P, DeFranco R, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P, Pinzani M. Nitrovasodilators inhibit plateled derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 2000, 119:479-492. 10.1053/gast.2000.9354, 10930383.
338. Klassen LW, Tuma D, Sorrell MF. Immune mechanisms of alcohol-induced liver disease. Hepatology 1995, 22:355-357.
339. Albano E. Free radical mechanisms in immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002, 32:110-114. 10.1016/S0891-5849(01)00773-0, 11796198.
340. Mottaran E, Stewart SF, Rolla R, Vay D, Cipriani V, Moretti M, Vidali M, Sartori M, Rigamonti C, Day CP, Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radic Biol Med 2002, 32:38-45. 10.1016/S0891-5849(01)00757-2, 11755315.
341. Thiele GM, Freeman TL, Klassen LW. mmunologic mechanisms of alcoholic liver injury. Semin Liver Dis 2004, 24:I273-287.
342. Rolla R, Vay D, Mottaran E, Parodi M, Traverso N, Aricó S, Sartori M, Bellomo G, Klassen LW, Thiele GM, Tuma DJ, Albano E. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000, 31:878-884. 10.1053/he.2000.5373, 10733543.
343. Stewart SF, Vidali M, Day CP, Albano E, Jones DE. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. Hepatology 2004, 39:197-203. 10.1002/hep.20021, 14752838.
344. Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 2005, 54:987-993. 10.1136/gut.2004.057968, 15951547.
345. Rigamonti C, Mottaran E, Reale E, Rolla R, Cipriani V, Capelli F, Boldorini R, Vidali M, Sartori M, Albano E. Moderate alcohol consumption increases oxidative stress in patients with chronic hepatitis C. Hepatology 2003, 38:42-49. 10.1053/jhep.2003.50275, 12829985.
346. Ronis MJ, Butura A, Korourian S, Shankar K, Simpson P, Badeaux J, Albano E, Ingelman-Sundberg M, Badger TM. Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. Exp Biol Med 2008, 233:344-355.
347. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783. 10.1038/nri1937, 16998510.
348. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006, 43:S54-62. 10.1002/hep.21060, 16447271.
349. Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007, 26:117-129. 10.1016/j.immuni.2006.11.011, 17239632.
350. Herkel J, Jagemann B, Wiegard C, Lazaro JF, Lueth S, Kanzler S, Blessing M, Schmitt E, Lohse AW. MHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes. Hepatology 2003, 37:1079-1085. 10.1053/jhep.2003.50191, 12717388.
351. Ma X, Hua J, Mohamood AR, Hamad AR, Ravi R, Li Z. A high-fat diet and regulatory T cells influence susceptibility to endotoxin-induced liver injury. Hepatology 2007, 46:1519-1529. 10.1002/hep.21823, 17661402.
352. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005, 42(Suppl 1):S22-36.
353. Chang CY, Argo CK, Al-Osaimi AMS, Caldwell SH. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2006, 40(Suppl 1):S51-60.
354. de Alwis NMW, Day CP. Non-alcoholic fatty liver: the mist gradually clear. J Hepatol 2008, 48(Suppl 1):S105-112.
355. Williams RJ, Spencer JP, Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic Biol Med 2004, 36:838-849. 10.1016/j.freeradbiomed.2004.01.001, 15019969.
356. Zhong Z, Froh M, Wheeler MD, Smutney O, Lehmann TG, Thurman RG. Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther 2002, 9:183-191. 10.1038/sj.gt.3301638, 11859421.
357. Okuyama H, Nakamura H, Shimahara Y, Uyama N, Kwon YW, Kawada N, Yamaoka Y, Yodoi J. Overexpression of thioredoxin prevents thioacetamide-induced hepatic fibrosis in mice. J Hepatol 2005, 42:117-123. 10.1016/j.jhep.2004.09.020, 15629516.
358. Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. Hepatology 2005, 42:335-342. 10.1002/hep.20803, 16025519.